The
investment narrative for
Bristol Myers Squibb (BMY) is continuously being shaped and recast, partly due to approval of their
Opdivo drug and recent
Eliquis pact trial update. Although there's been some sell-off of BMY shares by financial institutions, other firms are also taking new positions, often citing undervaluation. BMY has shown an impressive
33% ROE, and is noted for its strong growth and steady dividends. Approval of the pioneering
Breyanzi CAR T Therapy for rare Marginal Zone Lymphoma by the U.S. FDA has been critical and is a big win for BMY. The company is still seen as a compelling value stock even with recent share price rebound. Importantly, BMY's robust
pipeline and exploration into more therapies, bolstered by
Opdivo and
KarXT, show promising long-term growth prospects. The firm has also landed a deal with the US Government to enhance affordability and accessibility to essential drugs for Americans, despite recent dips in shares and a one-off loss, BMY is seen as an appealing option for long-term value investors. Lastly, more growth is expected, thanks to
Nivolumab, their latest drug.
Bristol-Myers Squibb BMY News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Sat, 10 Jan 2026 12:23:30 GMT -
Rating 7
- Innovation 7
- Information 8
- Rumor 5
